Daily Scoop : Geovax Labs (GOVX) Innovative Med Tech Will Rocket Up 🚀

$GeoVax Labs Inc(GOVX)$ 

So, what’s driving the action for the next Quarters for GOVX ?

The U.S. Patent and Trademark Office issued a “Notice of Allowance for Patent Application No. 17/000,768 titled, ‘Method for Generating a ZIKV Immune Response Utilizing a Recombinant Modified Vaccinia Ankara Vector Encoding the NS1 Protein.’”

If you haven’t heard of GeoVax, don’t feel bad. The company sports a tiny market capitalization and weighs in at just $32 million. According to the company, “GeoVax is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases.”

The company said its Zika vaccine candidate, GEO-ZM02, is “constructed using our modified vaccinia Ankara (MVA) vector platform.” According to its preclinical studies, a single dose of GeoVax’s GEO-ZM02 “provided 100% protection against a lethal dose of Zika virus.”

What to Make of GOVX Stock Right Now

There are some great developments happening for GeoVax, and we’re seeing that play out in GOVX stock — especially today.

However, it goes beyond what the company is doing with GEO-ZM02. In fact, according to GeoVax:

“Our lead program in oncology is Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Our lead infectious disease program is CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations, currently in two Phase 2 clinical trials.”

I understand this is a lot of medical gibberish to some investors who just want to know whether GOVX stock is a buy. Unfortunately, the answer to that question is not so simple.

The company is not exactly pre-revenue, but its revenue has recently gone to zero. It has not posted any revenue on its income statement in the last two quarters. That said, keep in mind this is a clinical-stage biotechnology.

So despite a reasonably solid balance sheet — where current assets are more than five-fold the company’s total liabilities — this falls under the category of speculation.

So when evaluating whether or not to buy GOVX stock, keep this in mind.

Go in at 1.40 or lower....